Randomized Controlled Trials (RCTs)

Randomized Controlled Trials (RCTs) are considered the “gold standard” of clinical research. They are experimental studies designed to evaluate the efficacy and safety of interventions (such as functional ingredients, adaptogens, or dietary supplements) by randomly allocating subjects into treatment and control groups.

Role in FTC Substantiation

Historically, the ftc described its requirement for competent-and-reliable-scientific-evidence (CRSE) as a “flexible” standard. However, recent updates to the FTC’s Health Products Compliance Guidance have formalized stricter expectations. Today, substantiating health-related benefits generally requires well-powered human RCTs.

To satisfy the FTC, RCTs must adhere to basic principles of valid scientific research:

• Control Groups and Randomization: Trials must feature a treatment group and a placebo/control group, utilizing randomization to prevent selection bias.
• Blinding: Double-blind studies (where neither the participants nor the researchers know who is receiving the treatment) are highly preferred to eliminate placebo effects and researcher bias.
• Peer Review and IRB Approval: Protocols should be clear, detailed, and ideally submitted to an Institutional Review Board (IRB) following Good Clinical Practice (GCP).

The FTC generally does not consider epidemiological studies, observational studies, animal/in vitro studies, or consumer anecdotes to be sufficient CRSE on their own. Furthermore, for specific disease-prevention claims, the FTC has established precedents (such as the 2010 consent decree with nestle) requiring a minimum of two well-controlled RCTs.